Malignant Glioma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Malignant Glioma – Drugs In Development, 2024 report and make more profitable business decisions.
Malignant gliomas are aggressive and fast-growing tumors that arise from glial cells in the brain and spinal cord. Gliomas account for the most common type of primary brain tumors in adults. Symptoms of malignant gliomas vary depending on the tumor’s size, location, and rate of growth. Common symptoms may include headaches, seizures, cognitive changes, personality or behavior changes, weakness or sensory loss, and difficulties with balance or coordination.
The Malignant Glioma drugs in development market research report provide comprehensive information on the therapeutics under development for Malignant Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malignant Glioma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Malignant Glioma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 68 molecules, with 53 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Malignant Glioma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Malignant Glioma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Malignant Glioma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Alaunos Therapeutics IncAstraZeneca Plc
Beijing Inno Medicine Co Ltd
Beijing Neoantigen Biotechnology Co Ltd
Bexion Pharmaceuticals Inc
Bionaut Labs Inc
Bristol-Myers Squibb Co
Candel Therapeutics Inc
Celularity Inc
CHA Biotech Co Ltd
Chimeric Therapeutics Ltd
China Medical University
City of Hope
Day One Biopharmaceuticals Inc
Duet Therapeutics Inc
Duke University
FUDA Cancer Hospital
Fuzhou Tcelltech Biological Science and Technology Inc
Gan & Lee Pharmaceuticals Co Ltd
Gibson Oncology LLC
Gilead Sciences Inc
Guangzhou Virotech Pharmaceutical Co Ltd
Hebei Senlang Biotechnology Co Ltd
Immix BioPharma Inc
Immunomic Therapeutics Inc
Immvira Co Ltd
Imvax Inc
Istari Oncology Inc
Jikei University School of Medicine
Keio University
Kidswell Bio Corp
Komipharm International Co Ltd
Laminar Pharmaceuticals SA
Lisata Therapeutics Inc
Moleculin Biotech Inc
NanoPharmaceuticals LLC
Nationwide Children's Hospital
Neonc Technologies Inc
Norwegian University of Science and Technology
Novartis AG
Oblato Inc
Ohio State University
OncoTherapy Science Inc
Orphelia Pharma SAS
Osaka University
PharmAbcine Inc
Philogen SpA
Pyramid Biosciences Inc
Rockefeller University
Royal Wuxi Biological Pharmaceutical Co Ltd
Simcere Pharmaceutical Group Ltd
Smerud Medical Research International AS
Starlight Therapeutics Inc
Stemline Therapeutics Inc
Sumitomo Pharma Co Ltd
Suzhou Maximum Bio-tech Co Ltd
Tactical Therapeutics Inc
Targepeutics Inc
UCLAs Jonsson Comprehensive Cancer Center
Universita Degli Studi Gd Annunzio Chieti Pescara
University Hospital Basel
Wayshine Biopharma Inc
Xiangxue Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Malignant Glioma reports